Visual Functioning and Mortality of Age-Related Macular Degeneration Patients in a Colorado Cohort
- PMID: 37437714
- PMCID: PMC10776804
- DOI: 10.1016/j.oret.2023.07.005
Visual Functioning and Mortality of Age-Related Macular Degeneration Patients in a Colorado Cohort
Abstract
Objective: To investigate the relationship between visual functioning as measured by the National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) and mortality in patients with various stages of age-related macular degeneration (AMD).
Design: Observational cohort study.
Participants: Patients with AMD enrolled in the University of Colorado AMD Registry between July 9, 2014 and December 31, 2021 were included.
Methods: Age-related macular degeneration cases were classified into early AMD, intermediate AMD, geographic atrophy, neovascular AMD, or both advanced types of AMD (neovasuclar and geographic atrophy both present) using multimodal imaging and the Beckman and Classification of Atrophy Meetings criteria. Visual Function Questionnaire -25 composite and subscale scores at the time of study enrollment were calculated. Cox proportional hazards modeling was used to assess time to event for mortality utilizing univariate and multivariable models, which adjusted for all variables significantly associated with mortality. The measures of association were hazard ratios (HRs) and 95% confidence intervals (CIs).
Main outcome measures: All-cause mortality statistics were obtained through a collaborative agreement with the Colorado Department of Public Health and Environment. Death rates through October 19, 2022 were compared by demographics and potential confounders.
Results: Analysis was completed on a cohort of 876 patients, of which 180 (20.6%) died during the follow-up period. Average follow-up time for this cohort was 52.5 (standard deviation: 26.6) months. In univariate analysis, composite VFQ-25 score and all subscale scores aside from ocular pain were significantly associated with time to mortality. Additionally, age, AMD category, marital status, history of smoking, and multiple chronic comorbid conditions were significantly associated with time to mortality. In multivariable analysis, for each 10-point increase in a patient's VFQ-25 scores for general health and driving, the risk of death decreased with HR of 0.85 (95% CI: 0.80, 0.91; P < 0.0001) and 0.92 (95% CI: 0.87, 0.97; P = 0.005), respectively. Composite and other subscale scores were not significantly associated with mortality after adjusting for confounding variables.
Conclusions: This cohort of AMD patients had a 20% rate of death in the 52.5-month average follow-up time. Better general health and ability to drive, as measured by the VFQ-25, were each separately associated with significantly lower risk of death among individuals with AMD.
Financial disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Keywords: Age-related macular degeneration (AMD); Driving ability; General health; Mortality; National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25).
Copyright © 2023 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of Interest:
No conflicting relationship exists for any author regarding the work in this publication.
Similar articles
-
Gender Differences in Visual Functioning Questionnaire Scores among Patients with Age-Related Macular Degeneration.Ophthalmic Epidemiol. 2023 Apr;30(2):186-195. doi: 10.1080/09286586.2022.2084756. Epub 2022 Jul 17. Ophthalmic Epidemiol. 2023. PMID: 35848204 Free PMC article.
-
Association between Patient-Reported Outcomes and Time to Late Age-Related Macular Degeneration in the Laser Intervention in Early Stages of Age-Related Macular Degeneration Study.Ophthalmol Retina. 2020 Sep;4(9):881-888. doi: 10.1016/j.oret.2020.03.015. Epub 2020 Mar 30. Ophthalmol Retina. 2020. PMID: 32418845 Clinical Trial.
-
The impact of advanced age-related macular degeneration on the National Eye Institute's Visual Function Questionnaire-25.Acta Ophthalmol. 2021 Nov;99(7):750-755. doi: 10.1111/aos.14731. Epub 2020 Dec 30. Acta Ophthalmol. 2021. PMID: 33377625
-
Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration.Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD013154. doi: 10.1002/14651858.CD013154.pub2. Cochrane Database Syst Rev. 2020. PMID: 33331670 Free PMC article.
-
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.Cochrane Database Syst Rev. 2019 Mar 4;3(3):CD005139. doi: 10.1002/14651858.CD005139.pub4. Cochrane Database Syst Rev. 2019. PMID: 30834517 Free PMC article.
Cited by
-
Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab.Pharmaceuticals (Basel). 2024 Jan 25;17(2):157. doi: 10.3390/ph17020157. Pharmaceuticals (Basel). 2024. PMID: 38399372 Free PMC article.
References
-
- Mangione CM. The National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25): Scoring algorithm with FAQ. https://www.nei.nih.gov/sites/default/files/2019-06/manual_cm2000.pdf. Published Aug 2000. Accessed Oct 4, 2022.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources